Loading
The 2003 paper that found the same breast cancer subtypes in other laboratories' data and showed that tumours from women with an inherited BRCA1 fault fall into the basal-like group, linking hereditary and triple-negative disease.
Sørlie, Tibshirani, Parker, Hastie and colleagues analysed 115 malignant breast tumours by hierarchical clustering on 534 intrinsic genes, selected for similar expression between paired samples from the same tumour taken 15 weeks apart during neoadjuvant treatment. The tumours subdivided into one basal-like, one ERBB2-overexpressing, two luminal-like and one normal breast tissue-like subgroup. Cluster analysis of two published independent data sets from different laboratories uncovered some of the same subtypes, and in the set with time to distant metastasis the subtypes differed significantly. Including tumours from BRCA1 carriers showed that this genotype predisposes to the basal tumour subtype.
The molecular bridge between germline BRCA1 and triple-negative breast cancer; it is why every triple-negative patient under 60 is now offered germline testing and why PARP inhibitors were tried in this disease first.
Confirmed the BRCA1 to basal link with a stain any laboratory could run, which is how the basal-like concept reached clinical pathology and how the Carolina Breast Cancer Study defined its subtypes three years later.
The origin of the intrinsic subtypes and of the word basal-like; triple-negative breast cancer is the clinical shadow of this molecular group, though the two overlap imperfectly.
Shares Molecular portraits of human breast tumours, Charles M. Perou, Proceedings of the National Academy of Sciences, PAM50 / intrinsic subtypes and the tag tnbc-evidence.
Shares Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer, Charles M. Perou, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares BRCA1 / BRCA2 (HRD), Germline (hereditary) testing, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares BRCA1 / BRCA2 (HRD), Germline (hereditary) testing, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares BRCA1 / BRCA2 (HRD), Germline (hereditary) testing, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares Charles M. Perou, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares BRCA1 / BRCA2 (HRD), Germline (hereditary) testing, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares BRCA1 / BRCA2 (HRD), Germline (hereditary) testing, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.